13.70
-0.1(-0.72%)
Currency In USD
| Previous Close | 13.8 |
| Open | 13.9 |
| Day High | 13.96 |
| Day Low | 13.29 |
| 52-Week High | 17.15 |
| 52-Week Low | 8.49 |
| Volume | 21,941 |
| Average Volume | 62,766 |
| Market Cap | 359.63M |
| PE | -13.17 |
| EPS | -1.04 |
| Moving Average 50 Days | 12.7 |
| Moving Average 200 Days | 12.88 |
| Change | -0.1 |
If you invested $1000 in Benitec Biopharma Inc. (BNTC) 10 years ago, it would be worth $8.18 as of September 28, 2025 at a share price of $13.7. Whereas If you bought $1000 worth of Benitec Biopharma Inc. (BNTC) shares 5 years ago, it would be worth $141.63 as of September 28, 2025 at a share price of $13.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Benitec Biopharma Provides Operational Updates
GlobeNewswire Inc.
Jul 09, 2025 12:00 PM GMT
-In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study (NCT06185673)- -Independent Data Safety Monitoring Board Review Has Been Completed for All Six Subjects
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
GlobeNewswire Inc.
Mar 25, 2025 12:00 PM GMT
HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-di
Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
GlobeNewswire Inc.
Mar 19, 2025 11:00 AM GMT
-Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1- -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for S